“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities

“Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they’re committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying from whole blood specific molecular markers of a patient’s immune system…”